Literature DB >> 24406212

p53 orchestrates between normal differentiation and cancer.

Noa Rivlin1, Gabriela Koifman2, Varda Rotter2.   

Abstract

During recent years, it is becoming more and more evident that there is a tight connection between abnormal differentiation processes and cancer. While cancer and stem cells are very different, especially in terms of maintaining genomic integrity, these cell types also share many similar properties. In this review, we aim to provide an over-view of the roles of the key tumor suppressor, p53, in regulating normal differentiation and function of both stem cells and adult cells. When these functions are disrupted, undifferentiated cells may become transformed. Understanding the function of p53 in stem cells and its role in maintaining the balance between differentiation and malignant transformation can help shed light on cancer initiation and propagation, and hopefully also on cancer prevention and therapy.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer stem cells; Differentiation; Stem cells; p53

Mesh:

Substances:

Year:  2014        PMID: 24406212     DOI: 10.1016/j.semcancer.2013.12.006

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  22 in total

Review 1.  Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation.

Authors:  Yoav Shetzer; Alina Molchadsky; Varda Rotter
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

2.  DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.

Authors:  Alejandro Parrales; Atul Ranjan; Swathi V Iyer; Subhash Padhye; Scott J Weir; Anuradha Roy; Tomoo Iwakuma
Journal:  Nat Cell Biol       Date:  2016-10-24       Impact factor: 28.824

3.  Lysine methylation represses p53 activity in teratocarcinoma cancer cells.

Authors:  Jiajun Zhu; Zhixun Dou; Morgan A Sammons; Arnold J Levine; Shelley L Berger
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-17       Impact factor: 11.205

4.  p53 is essential for DNA methylation homeostasis in naïve embryonic stem cells, and its loss promotes clonal heterogeneity.

Authors:  Ayala Tovy; Adam Spiro; Ryan McCarthy; Zohar Shipony; Yael Aylon; Kendra Allton; Elena Ainbinder; Noa Furth; Amos Tanay; Michelle Barton; Moshe Oren
Journal:  Genes Dev       Date:  2017-06-12       Impact factor: 11.361

5.  COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.

Authors:  Antje Lindemann; Ameeta A Patel; Jeffrey N Myers; Abdullah A Osman; Natalie L Silver; Lin Tang; Zhiyi Liu; Li Wang; Noriaki Tanaka; Xiayu Rao; Hideaki Takahashi; Nakachi K Maduka; Mei Zhao; Tseng-Cheng Chen; WeiWei Liu; Meng Gao; Jing Wang; Steven J Frank; Walter N Hittelman; Gordon B Mills
Journal:  Clin Cancer Res       Date:  2019-07-15       Impact factor: 12.531

6.  The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer.

Authors:  Angela M Krebs; Julia Mitschke; María Lasierra Losada; Otto Schmalhofer; Melanie Boerries; Hauke Busch; Martin Boettcher; Dimitrios Mougiakakos; Wilfried Reichardt; Peter Bronsert; Valerie G Brunton; Christian Pilarsky; Thomas H Winkler; Simone Brabletz; Marc P Stemmler; Thomas Brabletz
Journal:  Nat Cell Biol       Date:  2017-04-17       Impact factor: 28.824

Review 7.  Clinical Outcomes of TP53 Mutations in Cancers.

Authors:  Ana I Robles; Jin Jen; Curtis C Harris
Journal:  Cold Spring Harb Perspect Med       Date:  2016-09-01       Impact factor: 6.915

8.  Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition.

Authors:  Nabih Maslah; Emmanuelle Verger; Stéphane Giraudier; Mathias Chea; Ronald Hoffman; John Mascarenhas; Bruno Cassinat; Jean-Jacques Kiladjian
Journal:  Blood Adv       Date:  2022-05-10

9.  New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy.

Authors:  Gang Guo; Yan Cui
Journal:  J Immunother Cancer       Date:  2015-03-24       Impact factor: 13.751

10.  p53 Suppression partially rescues the mutant phenotype in mouse models of DiGeorge syndrome.

Authors:  Cinzia Caprio; Antonio Baldini
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.